Literature DB >> 6112387

Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis.

S P Hanley, J Bevan, S R Cockbill, S Heptinstall.   

Abstract

The capacity of venous tissue for prostacyclin synthesis was determined in 68 patients undergoing surgery for removal of varicose veins. A single dose of aspirin (81 mg or 300 mg) taken 14 h preoperatively strongly inhibited its synthesis, and the effect of 300 mg was still evident 48 h after ingestion. A single dose of 40 mg aspirin taken 14 h preoperatively had no effect on prostacyclin synthesis. The capacity of blood platelets to synthesise thromboxane (measured as malondialdehyde) was determined in volunteers before and at various times after ingestion of 300 mg or 40 mg aspirin. Both doses had an inhibitory effect that lasted for at least 96 h. The length of time for which the amount of thromboxane synthesised was insufficient to support platelet aggregation and the platelet release reaction depended on both the donor and the dose of aspirin. If prostacyclin and thromboxane are important in the pathogenesis of thrombosis, then doses of aspirin much lower than those used previously should be tested. The long-lasting effect of 300 mg aspirin on both venous tissue and platelets indicates that this dose is unlikely to produce a favourable prostacyclin/thromboxane balance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112387     DOI: 10.1016/s0140-6736(81)91733-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

Review 1.  Prostaglandins and the lung.

Authors:  S P Hanley
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 2.  The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.

Authors:  J A Oates
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

3.  Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.

Authors:  C Cerletti; M C Gambino; S Garattini; G de Gaetano
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.

Authors:  F Bochner; D B Williams; P M Morris; D M Siebert; J V Lloyd
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  The low dose aspirin controversy solved at last?

Authors:  R D Eastham
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-14

Review 6.  "But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-23

7.  [Importance of prostaglandins for the in vitro adhesiveness and in vivo margination of neutrophilic granulocytes].

Authors:  J Fehr; S Bütler
Journal:  Klin Wochenschr       Date:  1985-02-15

8.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

9.  Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies.

Authors:  M S Roberts; L J McLeod; P A Cossum; J H Vial
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Intimal thickening in autogenous vein grafts in rabbits: influence of aspirin and dipyridamole.

Authors:  A J Murday; A H Gershlick; Y D Syndercombe-Court; P G Mills; C T Lewis
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.